English
简体中文
Total: £ 56.28
Published Date: 2025-09-25 | Pages: 72 | Tables: 75 | Pharma & Healthcare
The global Ranibizumab market size was US$ 2805 million in 2024 and is forecast to a readjusted size of US$ 1367 million by 2031 with a CAGR of -9.9% during the forecast period 2025-2031.
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab.
The ranibizumab market is primarily driven by the increasing prevalence of eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and macular edema. As the global population ages and diabetes rates rise, the demand for effective treatments like ranibizumab continues to grow. Ranibizumab, an anti-VEGF (vascular endothelial growth factor) therapy, has proven highly effective in reducing vision loss and improving patient outcomes. Additionally, advancements in drug delivery methods, along with expanding healthcare access in emerging markets, are supporting the growth of the ranibizumab market.
One of the key challenges in the ranibizumab market is the high cost of the drug, which can limit patient access, particularly in developing countries or among uninsured populations. While biosimilar versions are being developed, affordability remains a concern. Additionally, there is growing competition from alternative therapies and biosimilars that offer similar efficacy at a lower price. Patient adherence to treatment regimens, which often require frequent intravitreal injections, can also be a challenge, as some patients may find the process uncomfortable or inconvenient.
Global core ranibizumab manufacturers include Roche and Novartis etc. The Top 2 companies hold a share about 98%. North America is the largest market, with a share about 51%, followed by Europe and Asia Pacific with the share about 28% and 20%.
The global Ranibizumab market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Roche
Coherus
Biogen
By Type: (Dominant Segment vs High-Margin Innovation)
Glass Vial
Prefilled Syringe
By Application: (Core Demand Driver vs Emerging Opportunity)
Wet AMD
Complications of Diabetes
RVO
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Roche in Europe)
- Emerging Product Trends: Glass Vial adoption vs. Prefilled Syringe premiumization
- Demand-Side Dynamics: Wet AMD growth in China vs. Complications of Diabetes potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Ranibizumab market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Prefilled Syringe in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Complications of Diabetes in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Ranibizumab value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Glass Vial
1.2.3 Prefilled Syringe
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Wet AMD
1.3.3 Complications of Diabetes
1.3.4 RVO
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ranibizumab Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Ranibizumab Revenue Market Share by Region (2020-2025)
2.4 Global Ranibizumab Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Ranibizumab Market Size and Prospective (2020-2031)
2.5.2 Europe Ranibizumab Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Ranibizumab Historic Market Size by Type (2020-2025)
3.2 Global Ranibizumab Forecasted Market Size by Type (2026-2031)
3.3 Different Types Ranibizumab Representative Players
4 Breakdown Data by Application
4.1 Global Ranibizumab Historic Market Size by Application (2020-2025)
4.2 Global Ranibizumab Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Ranibizumab Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Ranibizumab Players by Revenue (2020-2025)
5.1.2 Global Ranibizumab Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Ranibizumab Revenue
5.4 Global Ranibizumab Market Concentration Analysis
5.4.1 Global Ranibizumab Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Ranibizumab Revenue in 2024
5.5 Global Key Players of Ranibizumab Head office and Area Served
5.6 Global Key Players of Ranibizumab, Product and Application
5.7 Global Key Players of Ranibizumab, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Ranibizumab Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Ranibizumab Market Size by Type (2020-2025)
6.1.2.2 North America Ranibizumab Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Ranibizumab Market Size by Application (2020-2025)
6.1.3.2 North America Ranibizumab Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Ranibizumab Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Ranibizumab Market Size by Type (2020-2025)
6.2.2.2 Europe Ranibizumab Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Ranibizumab Market Size by Application (2020-2025)
6.2.3.2 Europe Ranibizumab Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
7 Key Players Profiles
7.1 Roche
7.1.1 Roche Company Details
7.1.2 Roche Business Overview
7.1.3 Roche Ranibizumab Introduction
7.1.4 Roche Revenue in Ranibizumab Business (2020-2025)
7.1.5 Roche Recent Development
7.2 Coherus
7.2.1 Coherus Company Details
7.2.2 Coherus Business Overview
7.2.3 Coherus Ranibizumab Introduction
7.2.4 Coherus Revenue in Ranibizumab Business (2020-2025)
7.2.5 Coherus Recent Development
7.3 Biogen
7.3.1 Biogen Company Details
7.3.2 Biogen Business Overview
7.3.3 Biogen Ranibizumab Introduction
7.3.4 Biogen Revenue in Ranibizumab Business (2020-2025)
7.3.5 Biogen Recent Development
8 Ranibizumab Market Dynamics
8.1 Ranibizumab Industry Trends
8.2 Ranibizumab Market Drivers
8.3 Ranibizumab Market Challenges
8.4 Ranibizumab Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Global Ranibizumab Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Ranibizumab Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Ranibizumab Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Ranibizumab Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Ranibizumab Revenue Share by Region (2020-2025)
Table 6. Global Ranibizumab Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Ranibizumab Revenue Share Forecast by Region (2026-2031)
Table 8. Global Ranibizumab Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Ranibizumab Revenue Market Share by Type (2020-2025)
Table 10. Global Ranibizumab Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Ranibizumab Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Ranibizumab Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Ranibizumab Revenue Market Share by Application (2020-2025)
Table 15. Global Ranibizumab Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Ranibizumab Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Ranibizumab Application
Table 18. Global Ranibizumab Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Ranibizumab Market Share by Players (2020-2025)
Table 20. Global Top Ranibizumab Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ranibizumab as of 2024)
Table 21. Ranking of Global Top Ranibizumab Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Ranibizumab Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Ranibizumab, Headquarters and Area Served
Table 24. Global Key Players of Ranibizumab, Product and Application
Table 25. Global Key Players of Ranibizumab, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Ranibizumab Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Ranibizumab Revenue Market Share by Company (2020-2025)
Table 29. North America Ranibizumab Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Ranibizumab Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Ranibizumab Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Ranibizumab Revenue Market Share by Company (2020-2025)
Table 33. Europe Ranibizumab Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Ranibizumab Market Size by Application (2020-2025) & (US$ Million)
Table 35. Roche Company Details
Table 36. Roche Business Overview
Table 37. Roche Ranibizumab Product
Table 38. Roche Revenue in Ranibizumab Business (2020-2025) & (US$ Million)
Table 39. Roche Recent Development
Table 40. Coherus Company Details
Table 41. Coherus Business Overview
Table 42. Coherus Ranibizumab Product
Table 43. Coherus Revenue in Ranibizumab Business (2020-2025) & (US$ Million)
Table 44. Coherus Recent Development
Table 45. Biogen Company Details
Table 46. Biogen Business Overview
Table 47. Biogen Ranibizumab Product
Table 48. Biogen Revenue in Ranibizumab Business (2020-2025) & (US$ Million)
Table 49. Biogen Recent Development
Table 50. Ranibizumab Market Trends
Table 51. Ranibizumab Market Drivers
Table 52. Ranibizumab Market Challenges
Table 53. Ranibizumab Market Restraints
Table 54. Research Programs/Design for This Report
Table 55. Key Data Information from Secondary Sources
Table 56. Key Data Information from Primary Sources
List of Figures
Figure 1. Ranibizumab Product Picture
Figure 2. Global Ranibizumab Market Share by Type: 2024 VS 2031
Figure 3. Glass Vial Features
Figure 4. Prefilled Syringe Features
Figure 5. Global Ranibizumab Market Share by Application: 2024 VS 2031
Figure 6. Wet AMD
Figure 7. Complications of Diabetes
Figure 8. RVO
Figure 9. Others
Figure 10. Ranibizumab Report Years Considered
Figure 11. Global Ranibizumab Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Ranibizumab Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Ranibizumab Revenue Market Share by Region: 2020 VS 2024
Figure 14. North America Ranibizumab Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. Europe Ranibizumab Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Global Ranibizumab Market Share by Players in 2024
Figure 17. Global Top Ranibizumab Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ranibizumab as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Ranibizumab Revenue in 2024
Figure 19. North America Ranibizumab Market Share by Type (2020-2025)
Figure 20. North America Ranibizumab Market Share by Application (2020-2025)
Figure 21. Europe Ranibizumab Market Share by Type (2020-2025)
Figure 22. Europe Ranibizumab Market Share by Application (2020-2025)
Figure 23. Roche Revenue Growth Rate in Ranibizumab Business (2020-2025)
Figure 24. Coherus Revenue Growth Rate in Ranibizumab Business (2020-2025)
Figure 25. Biogen Revenue Growth Rate in Ranibizumab Business (2020-2025)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
